{
    "clinical_study": {
        "@rank": "85822", 
        "acronym": "CaprelsaReg", 
        "arm_group": {
            "arm_group_label": "all Belgian patients treated with Caprelsa\u00ae (vandetanib)", 
            "description": "It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa\u00ae (vandetanib)."
        }, 
        "brief_summary": {
            "textblock": "In this registry it is planned to include all Belgian patients diagnosed with aggressive and\n      symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who\n      have been prescribed Caprelsa\u00ae (vandetanib).\n\n      The characteristics of patients receiving Caprelsa\u00ae (vandetanib) will be described.\n      Therefore real life data regarding demographic characteristics, evolution of the disease,\n      RET mutation status, the treatment before, during and after vandetanib, dose and duration of\n      treatment with Caprelsa\u00ae (vandetanib) and time of progression or death (if applicable) will\n      be included."
        }, 
        "brief_title": "CAPRELSA\u00ae REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa\u00ae) in Current Clinical Practice", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "All Belgian Patients With Aggressive, Symptomatic Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer and Taking Caprelsa\u00ae Will be Included.", 
        "condition_browse": {
            "mesh_term": [
                "Aggression", 
                "Thyroid Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n        The subject population that will be observed in this registry, must fulfil all of the\n        following criteria:\n\n          1. Provision of subject Informed Consent\n\n          2. Patients diagnosed with aggressive and symptomatic unresectable locally advanced or\n             metastatic MTC\n\n          3. Patients who already received a prescription for vandetanib in accordance with the\n             scientific leaflet and fulfilling the reimbursement criteria of vandetanib and who\n             are currently treated or have been treated with vandetanib 100 mg or 300 mg tablets.\n\n        The prescription of the medicinal product is clearly separated from the decision to\n        include the subject in the registry.\n\n        Exclusion criteria Not applicable since patients participating in another study can take\n        part in this registry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "It is planned to include all Belgian sites which have patients diagnosed with aggressive\n        and symptomatic unresectable locally advanced or metastatic MTC who have been prescribed\n        vandetanib and fulfilling the criteria for reimbursement."
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02109250", 
            "org_study_id": "D4200R00001"
        }, 
        "intervention": {
            "arm_group_label": "all Belgian patients treated with Caprelsa\u00ae (vandetanib)", 
            "description": "Caprelsa\u00ae 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.", 
            "intervention_name": "Caprelsa", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Medullary Thyroid Cancer (MTC) vandetanib caprelsa", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Philippe Glorieux, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Arlon", 
                        "country": "Belgium", 
                        "zip": "6700"
                    }, 
                    "name": "Clinique du Sud Luxembourg"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Verhoeven Didier, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Brasschaat", 
                        "country": "Belgium", 
                        "zip": "2930"
                    }, 
                    "name": "AZ Klina"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cornelis Frank, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "UCL St-Luc"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lore Decoster, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1090"
                    }, 
                    "name": "UZ Brussel"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simon Van Belle, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "UZ Gent"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jean-Marie Vandenbulcke, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Tournai", 
                        "country": "Belgium", 
                        "zip": "7500"
                    }, 
                    "name": "CH de Wallonie"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "CAPRELSA\u00ae REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa\u00ae) in Current Clinical Practice", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Veronique Deschamp", 
            "phone": "+32 2 370 48 11"
        }, 
        "overall_official": {
            "affiliation": "UZ Brussel", 
            "last_name": "Lore Decoster, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In this registry the following real life data will be collected: demographic characteristics, evolution of the disease, RET mutation status, the treatment before, during and after vandetanib, dose and duration of treatment with vandetanib and time of progression or death (if applicable).", 
            "measure": "The primary objective of this registry is to describe the characteristics of patients who receive Caprelsa\u00ae and who are fulfilling the reimbursement criteria.", 
            "safety_issue": "No", 
            "time_frame": "Up to 16 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02109250"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Case-Only", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "16 Months", 
        "verification_date": "May 2014"
    }
}